검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Checkpoint Inhibitor, Immune (Checkpoint Inhibitor, Immune) EpicentRx, Inc.·Solid Tumor, Adult ORR 59% |
|---|---|
Overview Program | Checkpoint Inhibitor, Immune |
Overview Company | EpicentRx, Inc. |
Overview Modality | CGT |
Overview Target | Solid Tumor, Adult |
Overview Indication | Solid Tumor, Adult; Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | checkpoint inhibitor-induced colitis |
MoA Biomarker | Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Checkpoint Inhibitor Immune-Related Adverse Events: A Multimodality Pictorial Review.. Cancer immunotherapies are drugs that modulate the body's own immune system as an anticancer strategy. Checkpoint inhibitor immunotherapies interfere with cell surface binding proteins that function to promote self-recognition and tolerance, ultimately leading to upregulation of the immune response. Given the st… |
Clinical Primary efficacy | ORR 59% |
Clinical ORR | 59% |
Clinical Result source | ClinicalTrials.gov NCT03729245 |
Clinical Data Tier / Score | A · 55 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Checkpoint Inhibitor, Immune (Checkpoint Inhibitor, Immune) EpicentRx, Inc.·Solid Tumor, Adult ORR 59% |
|---|---|
Overview Program | Checkpoint Inhibitor, Immune |
Overview Company | EpicentRx, Inc. |
Overview Modality | CGT |
Overview Target | Solid Tumor, Adult |
Overview Indication | Solid Tumor, Adult; Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | checkpoint inhibitor-induced colitis |
MoA Biomarker | Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Checkpoint Inhibitor Immune-Related Adverse Events: A Multimodality Pictorial Review.. Cancer immunotherapies are drugs that modulate the body's own immune system as an anticancer strategy. Checkpoint inhibitor immunotherapies interfere with cell surface binding proteins that function to promote self-recognition and tolerance, ultimately leading to upregulation of the immune response. Given the st… |
Clinical Primary efficacy | ORR 59% |
Clinical ORR | 59% |
Clinical Result source | ClinicalTrials.gov NCT03729245 |
Clinical Data Tier / Score | A · 55 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교